Avalo Therapeutics (AVTX) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Avalo Therapeutics (AVTX) has outperformed Verastem (VSTM) over the past year, gaining 0.7% versus a loss of 8.2%. Over five years, VSTM leads with a -75.0% price change compared with -99.8% for AVTX. Verastem is the larger company by market cap ($748.5 million vs $728.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTX | VSTM |
|---|---|---|
| Share price | $13.58 | $8.27 |
| Market cap | $728.30M | $748.51M |
| 1-day change | -0.07% | +6.65% |
| YTD return | -25.22% | +7.06% |
| 1-year return | +0.74% | -8.17% |
| 5-year return | -99.79% | -75.05% |
| EPS (TTM) | $-4.31 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.27 | $10.82 |
| 52-week low | $12.51 | $3.43 |
| Distance from 52-week high | -44.05% | -23.61% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +224.59% | +77.50% |
| Average volume | 929.44K | 2.26M |
| Shares outstanding | 53.63M | 90.56M |
| Employees | 33 | 102 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Healthcare · Biotechnology · 33 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Healthcare · Biotechnology · 102 employees
AVTX vs VSTM FAQ
Which is bigger, Avalo Therapeutics or Verastem?
Verastem (VSTM) is larger, with a market capitalization of $748.51M compared with $728.30M for Avalo Therapeutics (AVTX).
Which stock has performed better over the past year, AVTX or VSTM?
AVTX returned +0.74% over the past 12 months, compared with -8.17% for VSTM (price return, excluding dividends). Past performance does not predict future results.
Are Avalo Therapeutics and Verastem in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.